Most people agree reimbursement that rewards volume has fueled overuse and high costs for U.S. healthcare. But few agree on the best replacement. François de Brantes, executive director of the Health Care Incentives Improvement Institute, made a case for pay-for-performance incentives recently in the Wall Street Journal. Steffie Woolhandler, MD, MPH, of the City University of New York School of Public Health, shared why she thinks it is a bad idea.

Eugene Sherman, MD, chair of the American College of Cardiology’s Advocacy Steering Committee and Political Action Committee, shares his experience meeting with other cardiovascular societies to make a case to members of Congress to eliminate the Sustainable Growth Rate formula and boost healthcare quality in a blog post.

The first project to receive an investment from the American Heart Association’s Science & Technology Accelerator Program will be jointly developed by CytoVas, LLC and BD Biosciences, the firms announced.

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the results of a POZEN sponsored study at the Academy of Managed Care Pharmacy’s 25th Annual Meeting and Expo on April 4, 2013. 

Atrial fibrillation (AF) places a heavy financial burden on the U.S. healthcare system, but cardiologists may help to chip away at these costs.

Despite data supporting the clinical benefits of remote monitoring, some practices are resisting adoption due to the potential liability of receiving alerts on a 24-hour basis. Four experts share their opinions on how practices should approach these considerations.

Since the clinical benefits of fractional flow reserve (FFR) were confirmed with the release of the FAME study in January 2009, the technology has gained wider adoption. To assess its impact on contemporary cath labs, five interventionalists came together from across the U.S. to discuss the economic considerations.